Cost-effectiveness Analysis of Reference Infliximab (Remicade) Compared to its Biosimilar (Remsima) in Iraqi Patients with Rheumatoid Arthritis

Authors
Category Primary study
JournalIraqi Journal of Pharmaceutical Sciences
Year 2022
This article has no abstract
Epistemonikos ID: 2248bb689e219eb35f5672d67a0487f087956ef3
First added on: Feb 15, 2025